Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8504 Monotherapy in ART-Naïve HIV-1
NCT03188523Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of tenofovir prodrug MK-8504 in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA), Number of Participants Who Experienced At Least One Adverse Event (AE) up to 25 days and 1 more. Started Sep 2017; status: completed.
02
Drugs
tenofovir prodrug MK-8504
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03188523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03188523.